publication date: Oct. 26, 2018

Conversation with The Cancer Letter

NCI’s Korde: Follow-up needed to validate PFS with mature OS results for Tecentriq

Larissa Korde

Larissa Korde

Head of Breast Cancer Therapeutics, Clinical Investigations Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI


Matthew Ong:

What are your thoughts about the NEJM paper on atezolizumab in triple-negative breast cancer?

Larissa Korde:

Triple negative breast cancer patients have a poor prognosis, and the only current treatment option is chemotherapy, so this is definitely a patient population in whom additional treatments are needed. Immunotherapy has generated a great deal of interest because of robust and durable responses in other tumor types, such as lung cancer and melanoma.

Reported response rates for preliminary studies of immune checkpoint monotherapy in breast cancer have been relatively low; in comparison, though, the results of preliminary studies of checkpoint blockade combined with chemotherapy have been more promising. This is the first phase III study of checkpoint blockade reported in breast cancer .



Could you describe the study design?


The study enrolled patients regardless of the PD-L1 status and was designed with PFS and OS as co-primary endpoints.

The protocol specified that the analysis of PFS would be conducted in both the intent-to-treat population and the PD-L1 positive subset.

For OS, the protocol … Continue reading NCI’s Korde: Follow-up needed to validate PFS with mature OS results for Tecentriq

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.